ORAL SCAN: Effects Of The Oral JAK Inhibitor Tofacitinib In Combination With Methotrexate On Patient Reported Outcomes In a 24-Month Phase 3 Trial Of Active Rheumatoid Arthritis

被引：0
|
作者：
Strand, V. [1 ]
van der Heijde, D. [2 ]
Zerbini, C. A. F. [3 ]
Connell, C. A. [4 ]
Gruben, D. [4 ]
Riese, R. [4 ]
Wallenstein, G. [4 ]
机构：
[1] Stanford Univ, Palo Alto, CA 94304 USA
[2] Leiden Univ, Med Ctr, Leiden, Netherlands
[3] Ctr Paulista Invest Clin, Sao Paulo, Brazil
[4] Pfizer Inc, Groton, CT 06340 USA
来源：
ARTHRITIS AND RHEUMATISM | 2013年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2334
引用
收藏
页码：S996 / S997
页数：2
相关论文
共 50 条
  • [1] Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan study
    Strand, V
    van der Heijde, D.
    Tanaka, Y.
    Keystone, E.
    Kremer, J.
    Zerbini, C. A. F.
    Cardiel, M. H.
    Cohen, S.
    Nash, P.
    Song, Y-W
    Tegzova, D.
    Gruben, D.
    Wallenstein, G.
    Connell, C. A.
    Fleischmann, R.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2020, 38 (05) : 848 - 857
  • [2] ORAL START: EFFECTS OF THE ORAL JAK INHIBITOR TOFACITINIB MONOTHERAPY VERSUS METHOTREXATE ON PATIENT-REPORTED OUTCOMES IN THE PHASE 3 ORAL START TRIAL OF ACTIVE RHEUMATOID ARTHRITIS
    Strand, V.
    Fleischmann, R.
    Alten, R. E.
    Koncz, T.
    Zwillich, S. H.
    Bradley, J. D.
    Gruben, D.
    Wilkinson, B.
    Krishaswami, S.
    Wallenstein, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 252 - 253
  • [3] Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial
    Strand, Vibeke
    Lee, Eun Bong
    Fleischmann, Roy
    Alten, Rieke E.
    Koncz, Tamas
    Zwillich, Samuel H.
    Gruben, David
    Wilkinson, Bethanie
    Krishnaswami, Sriram
    Wallenstein, Gene
    RMD OPEN, 2016, 2 (02):
  • [4] TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR: PATIENT REPORTED OUTCOMES IN AN AUSTRALIAN PHASE 3 RHEUMATOID ARTHRITIS STUDY POPULATION
    Hall, S.
    Nash, P.
    Rischmueller, M.
    Bossingham, D.
    Cook, N.
    Witcombe, D.
    Kwok, K.
    Thirunavukkarasu, K.
    INTERNAL MEDICINE JOURNAL, 2013, 43 : 11 - 11
  • [5] Tofacitinib (CP-690,550), An Oral Janus Kinase Inhibitor, in Combination with Methotrexate Reduced the Progression of Structural Damage in Patients with Rheumatoid Arthritis: a 24-Month Phase 3 Study.
    van der Heijde, Desiree
    Tanaka, Y.
    Fleischmann, Roy
    Keystone, Edward C.
    Kremer, J. M.
    Zerbini, C. A. F.
    Cardiel, M.
    Cohen, S. B.
    Nash, P. T.
    Song, Yeong Wook
    Tegzova, D.
    Wyman, B.
    Gruben, D.
    Benda, B.
    Wallenstein, G.
    Zwillich, S. H.
    Bradley, J. D.
    Connell, C. A.
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S1017 - S1018
  • [6] EFFECTS OF TOFACITINIB (CP-690,550), AN ORAL JANUS KINASE INHIBITOR, OR ADALIMUMAB ON PATIENT REPORTED OUTCOMES IN A PHASE 3 STUDY OF ACTIVE RHEUMATOID ARTHRITIS
    van Vollenhoven, R. F.
    Wallenstein, G.
    Lee, E. B.
    Fleischmann, R.
    Zwillich, S. H.
    Gruben, D.
    Koncz, T.
    Bradley, J.
    Wilkinson, B.
    Strand, V.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 206 - 206
  • [7] EFFECTS OF TOFACITINIB MONOTHERAPY VERSUS METHOTREXATE ON PATIENT-REPORTED OUTCOMES IN THE 2-YEAR PHASE 3 ORAL START TRIAL IN METHOTREXATE-NAIVE PATIENTS WITH RHEUMATOID ARTHRITIS
    Alten, R.
    Strand, V.
    Fleischmann, R.
    Koncz, T.
    Zwillich, S.
    Bradley, J.
    Gruben, D.
    Wilkinson, B.
    Krishnaswami, S.
    Wallenstein, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 118 - 119
  • [8] Tofacitinib, an Oral Janus Kinase Inhibitor, in Combination with Methotrexate Reduced the Progression of Structural Damage in Patients with Rheumatoid Arthritis: Year 2 Efficacy and Safety Results From a 24-Month Phase 3 Study
    van der Heijde, D.
    Tanaka, Y.
    Fleischmann, R. M.
    Keystone, E.
    Kremer, J. M.
    Zerbini, C.
    Cardiel, M. H.
    Cohen, S. B.
    Nash, P. T.
    Song, Y.
    Tegzova, D.
    Wyman, B.
    Gruben, D.
    Benda, B.
    Wallenstein, G.
    Krishnaswami, S.
    Zwillich, S. H.
    Bradley, J.
    Connell, C. A.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S546 - S547
  • [9] EFFECTS OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, ON PATIENT-REPORTED OUTCOMES IN JAPANESE PATIENTS WITH RHEUMATOID ARTHRITIS
    Yamanaka, H.
    Tanaka, Y.
    Takeuchi, T.
    Sugiyama, N.
    Hirose, T.
    Yoshii, N.
    Morishima, Y.
    Toyoizumi, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 274 - 275
  • [10] Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial
    Strand, Vibeke
    Mysler, Eduardo
    Moots, Robert J.
    Wallenstein, Gene, V
    DeMasi, Ryan
    Gruben, David
    Soma, Koshika
    Iikuni, Noriko
    Smolen, Josef S.
    Fleischmann, Roy
    RMD OPEN, 2019, 5 (02):
12345